Fouzia Laghrissi-Thode, DalCor Pharmaceuticals CEO
September 13, 2023 11:29 AM EDT
Financing
R&D

Af­ter an $80M Se­ries D raise, Dal­Cor takes an­oth­er shot at a PhI­II my­ocar­dial in­farc­tion tri­al

Ayisha Sharma

News Reporter

Dal­Cor Phar­ma­ceu­ti­cals has re­grouped from past set­backs to com­plete an $80 mil­lion Se­ries D round to ad­vance its cho­les­teryl es­ter trans­fer pro­tein (CETP) in­hibitor, dal­cetrapib …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times